 ROCKVILLE, Md.--BUSINESS WIRE--GlycoMimetics, Inc. Nasdaq: GLYC today announces that an abstract presenting the interim analysis of a Phase 1b proof-of-concept study of GMI-1359, the Companys dual antagonist of E-selectin and CXCR4, has been accepted for presentation at the American Association of Cancer Research AACR 2021 Annual Meeting, to be held virtually on April 10-15 and May 17-21. Preclinical studies indicate that targeting both E-selectin and CXCR4, a chemokine receptor, with a 